Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Amgen (Germany)
h-index: 73
Total citations: 21,019
Total papers: 592
Homepage:
https://www.amgen.de/
Recent papers from Amgen (Germany)
Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia
New England Journal of Medicine · 2026
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial
Lung Cancer · 2026
Integrating T cell signaling and metabolism to enhance T cell engager responses in solid tumors
Frontiers in Immunology · 2026
Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer
Advances in Therapy · 2026
TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome
Leukemia · 2026
Statisticians at the Forefront of Health Technology Assessment: Aligning Regulatory and HTA Evidence Through Transdisciplinary Collaboration
Statistics in Biopharmaceutical Research · 2026
Abstract 7762: PD-L1-dependent 4-1BB costimulation enhances anti-tumor efficacy and T cell persistence as monotherapy or in combination with tarlatamab
Cancer Research · 2026
Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL1731
Blood · 2025
Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study
Leukemia · 2025
Derivation of Meaningful Change Thresholds for European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-LC13 in Patients With Small-Cell Lung Cancer
Value in Health · 2025
Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies
Clinical Research in Cardiology · 2025
Efficacy Outcomes Between Tarlatamab and Real-World Physicians’ Choice of Therapies for Previously Treated Extensive Stage Small Cell Lung Cancer
The Oncologist · 2025
Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T‐Cell Engager, in Prostate Cancer Patients
The Journal of Clinical Pharmacology · 2025
BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
Leukemia & lymphoma/Leukemia and lymphoma · 2025
Surface Plasmon Resonance Based Binding Characterization for Screening RNA-Loaded Lipid Nanoparticles (LNPs): Exploring Species Cross-Reactivity in LNP–Apolipoprotein E Interactions
Molecular Pharmaceutics · 2025
Treatment Patterns, Goals, and Decision-Making Criteria for Second- and Third-Line Therapies for Multiple Myeloma in Germany
Advances in Therapy · 2025
Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells
Journal of the American Chemical Society · 2025
Pooled biomarker analysis of the association of baseline T regulatory cells with response and T-cell recovery profiles with blinatumomab treatment
The Oncologist · 2025
The Current Landscape of HTA Framework and Key Challenges
Statistics in Biopharmaceutical Research · 2025
Disparities in achieving low-density lipoprotein cholesterol goals after revascularization in a diverse real-world cohort
European Journal of Preventive Cardiology · 2025